Patents by Inventor Roel Funke

Roel Funke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIAGNOSTIC AND THERAPEUTIC METHODS FOR TRIPLE-NEGATIVE BREAST CANCER
    Publication number: 20210208145
    Abstract: The invention provides methods and compositions for diagnosing and treating locally advanced or metastatic breast cancer (e.g., TNBC). In some embodiments, the methods include determining the presence and/or expression level of one or more of PD-L1, CD8, and/or stromal tumor-infiltrating lymphocytes (sTILs). Provided herein are methods for identifying a patient suffering from a locally advanced or metastatic TNBC who is likely to respond to treatment with an anti-cancer therapy that includes a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody (e.g., atezolizumab) or an anti-PD-1 antibody) and a taxane (e.g., nab-paclitaxel or paclitaxel). Also provided are methods of selecting a therapy for a patient suffering from a locally advanced or metastatic TNBC. Further provided are methods of treating a patient suffering from locally advanced or metastatic TNBC. In some embodiments, the methods include administering a PD-1 axis binding antagonist (e.g., atezolizumab) and a taxane (e.g.
    Type: Application
    Filed: March 19, 2021
    Publication date: July 8, 2021
    Inventors: Luciana Lorena MOLINERO, Stephen CHUI, Roel FUNKE
  • DOSING FOR TREATMENT WITH ANTI-EGFL7 ANTIBODIES
    Publication number: 20130004498
    Abstract: The present invention concerns dosing of anti-EGFL7 antibodies for cancer therapy.
    Type: Application
    Filed: February 1, 2012
    Publication date: January 3, 2013
    Applicant: Genentech, Inc.
    Inventors: Shuang Bai, Daniel S. Chen, Roel Funke, Priti Hegde, Louie Naumovski
  • HPRP4s Modifiers of the p53 Pathway and Methods of Use
    Publication number: 20070160539
    Abstract: Human hPRP4 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of hPRP4 are provided.
    Type: Application
    Filed: January 26, 2007
    Publication date: July 12, 2007
    Applicant: EXELIXIS, INC.
    Inventors: Lori Friedman, Gregory Plowman, Tak Hung, Helen Francis-Lang, Danxi Li, Roel Funke, Michael Costa
  • Lces as modifiers of the p53 pathway and methods of use
    Publication number: 20070134732
    Abstract: Human LCE genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of LCE are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: June 14, 2007
    Inventors: Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke
  • Sphks as modifiers of the p53 pathway and methods of use
    Publication number: 20060252035
    Abstract: Human SPHK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SPHK are provided.
    Type: Application
    Filed: August 2, 2002
    Publication date: November 9, 2006
    Inventors: Lori Friedman, Gregory Plowman, Michael Costa, Danxi Li, Roel Funke, Tak Hung
  • LIMKs as modifiers of p53 pathway and methods of use
    Publication number: 20060160764
    Abstract: Human LIMK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of LIMK are provided.
    Type: Application
    Filed: March 17, 2006
    Publication date: July 20, 2006
    Applicant: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke
  • Gfats as modifiers of the p53 pathway and methods of use
    Publication number: 20060121457
    Abstract: Human GFAT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of GFAT are provided.
    Type: Application
    Filed: June 2, 2002
    Publication date: June 8, 2006
    Inventors: Lori Friedman, Gregory Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke
  • Gpcs as modifiers of the irrtk p21 pathways and methods of use
    Publication number: 20060121041
    Abstract: Human GPC genes are identified as modulators of the IRRTK or p21 pathways, and thus are therapeutic targets for disorders associated with defective IRRTK or p21 function. Methods for identifying modulators of IRRTK or p21, comprising screening for agents that modulate the activity of GPC are provided.
    Type: Application
    Filed: July 10, 2002
    Publication date: June 8, 2006
    Inventors: Lori Friedman, Gregory Plowman, Tom Kidd, Roel Funke, Danxi Li, Siobhan Roche
  • PRMTs as modifiers of the p53 pathway and methods of use
    Publication number: 20060024665
    Abstract: Human PRMT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of PRMT are provided.
    Type: Application
    Filed: September 30, 2005
    Publication date: February 2, 2006
    Inventors: Lori Friedman, Gregory Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke, Rolf Ryseck, Lata Jayaraman, David Bol, Matthew Lorenzi
  • Slc2as as modifiers of the p53 pathway and methods of use
    Publication number: 20060024673
    Abstract: Human SLC2A genes are identified as modulators of the p53 pathway, and thus as therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SLC2A are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: February 2, 2006
    Inventors: Lori Friedman, Gregory Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke
  • Map3ks as modifiers of the p53 pathway and methods of use
    Publication number: 20050227228
    Abstract: Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: October 13, 2005
    Inventors: Lori Friedman, Gregory Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke
  • HADHs as modifiers of the p21 pathway and methods of use
    Publication number: 20050186200
    Abstract: Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.
    Type: Application
    Filed: April 11, 2005
    Publication date: August 25, 2005
    Inventors: Lori Friedman, Gregory Plowman, Roel Funke, Marcia Belvin, Danxi Li, Stephanie Robertson
  • PRMTs as modifiers of the p53 pathway and methods of use
    Publication number: 20050186566
    Abstract: Human PRMT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of PRMT are provided.
    Type: Application
    Filed: June 5, 2002
    Publication date: August 25, 2005
    Inventors: Lori Friedman, Gregory Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke, Rolf Ryseck, Lata Jayaraman, David Bol, Matthew Lorenzi
  • HADHs as modifiers of the p21 pathway and methods of use
    Publication number: 20050181481
    Abstract: Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.
    Type: Application
    Filed: April 11, 2005
    Publication date: August 18, 2005
    Inventors: Lori Friedman, Gregory Plowman, Roel Funke, Marcia Belvin, Danxi Li, Stephanie Robertson
  • Chds as modifiers of the p53 pathway and methods of use
    Publication number: 20050170344
    Abstract: Human CHD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of CHD are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: August 4, 2005
    Inventors: Lori Friedman, Gregory Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke, Mario Lioubin
  • Dgks as modifiers of the p53 pathwha and methods of use
    Publication number: 20050112568
    Abstract: Human DGK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53,comprising screening for agents that modulate the activity of DKG are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: May 26, 2005
    Inventors: Lori Friedman, Gregory Plowman, Mercia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke